This “Safe” Stock Is Suddenly Setting Up for a Major Move

While investors obsess over the latest flashy growth stories, one of the market’s most disciplined blue-chip leaders is quietly stepping back into the spotlight. This stock is long known for its resilience and scientific depth, and is entering a new phase where innovation pipelines and strategic focus are finally converging. Its next-generation therapies are advancing through key clinical stages, its medical technology division is accelerating with stronger demand trends, and its post-spinoff profile is looking more streamlined than ever. Layer in improving sentiment, a strengthening fundamentals-driven uptrend, and a chart that’s beginning to reflect renewed institutional accumulation—and is starting to look less like a defensive hold and more like a sleeper setup with meaningful upside ahead.

Right now, Johnson & Johnson (JNJ), is also flashing a constructive technical signal, with the 50-day EMA trading firmly above the 100-day EMA—an indication that underlying momentum is strengthening rather than stalling out. And in a market that’s been slipping into another bout of turbulence, that relative stability stands out. While many stocks are starting to wobble under pressure, JNJ’s price action has remained orderly, supportive, and increasingly aligned with its improving fundamental outlook. The trend is tightening, the signals are pointing in the right direction, and the stock is beginning to show the kind of steady accumulation that often precedes a more decisive move. For traders, that combination of technical confirmation and defensive strength creates a compelling window to consider a bullish setup.

🧠 Learn the art of options trading with expert guidance from champion trader Chuck Hughes. Gain a step-by-step plan to confidently learn about trading options, how Chuck manages risks effectively, and more. Embark on your path to today! 🚀

For this setup, I’m looking to step into JNJ with an in-the-money call debit spread — a structure that lets me capitalize on the strengthening trend while keeping risk clearly defined. With the 50-day EMA trading above the 100-day EMA and momentum steadily improving, the technical backdrop supports a continuation move higher. Rather than reaching for expensive outright calls, this in-the-money spread gives me strong directional exposure with a more efficient break-even profile. At current pricing, the spread offers a 53.8% profit potential, and it can still generate a gain even if JNJ pulls back up to 7.5% into expiration. That’s exactly the type of setup I look for — a bullish position that doesn’t require a flawless move to deliver a solid return.

If you’re serious about sharpening your chart skills and getting trade setups you can actually use each week, then our Weekly Workshop video newsletter is where you need to be. Every edition breaks down the market through clean, practical technical analysis—plus multiple actionable trades, complete with step-by-step video walkthroughs that show you exactly what we’re seeing and why it matters. And right now, you can test-drive the entire experience for just $1 for your first month. That’s not a typo—four full weeks of pro-level market analysis for less than the spare change in your car cupholder. This offer won’t be around forever, and the next batch of setups is already lining up. If you want the next round of trade alerts to hit your inbox, this is your moment, go ahead and claim your trial now!

Wishing You the Best in Investing Success,